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Introduction
Enteric fever is a global health problem responsible for
21million cases and 21,000 deaths annually. Of these 80% of
cases occur in Asia alone.1 Pakistan is a high burden country
with an annual incidence of 413 /100,000 person / year.1 Even
in 21st century many challenges limit its effective management.
One of the major issues is emergence of drug resistant strains.
Initially chloramphenicol was successfully used to
treat this infection but in 1980s emergence of resistance
limited its use.2 This was followed by emergence of
multidrug resistant (MDR) strains2 (combined resistance to
chloramphenicol, ampicillin and co-trimoxazole) initially
reported from India, Pakistan and Middle East and then from
all over the world. Emergence of this resistance results in loss
of these cost effective drugs making fluoroquinolones the
drug of choice.2,3 However widespread use of
fluoroquinolones led to emergence of Salmonella Enterica
serovar Typhi and Paratyphi strains with reduced
susceptibility to fluoroquinolones.3,4
Currently third generation cephalosporins are the
mainstay to treat enteric fever. However, isolation of S. Typhi
resistant to ceftriaxone from Bangladesh5 and reports of
clinical strains with higher minimum inhibitory concentration
(MIC) from India is alarming6,7 and leave very limited
therapeutic options to treat this infection.
This emerging resistance in ceftriaxone makes this
situation worse and enforces scientist to seek out newer
options for treatment of typhoid fever. Recently clinical and
laboratory based studies have reported good activity of
azithromycin8,9 imipenem10 and pefloxacin11,12 against
enteric fever isolates, building these drugs as satisfactory
alternatives to conventional drugs. Additionally, cefipime,13 a
fourth generation cephalosporin is reported to have improved
coverage for resistant gram negative pathogen; however its
role in enteric fever needs to be evaluated. Therefore, this
study was conducted to explore the future use of
azithromycin, pefloxacin, imipenem and cefipime by
determining their MICs against enteric fever isolates. MICs
of ceftriaxone and susceptibility patterns of conventional
drug were also assessed for all isolates of S. Typhi and S.
Paratyphi A, B and C included in the study. 
Materials and Methods
This study was conducted at the clinical microbiology
laboratory of the Aga Khan University (AKUH), Karachi
Pakistan. AKUH is a tertiary care centre and its microbiology
laboratory receives blood culture both from admitted patients
and outpatients collected through 189collection points
located all over the country. 
One hundred and fifty four (154) clinical strains of S.
Typhi and S. Paratyphi A, B and C isolated from blood
culture between March 2007 and August 2007 were included
in this study.
Blood cultures received in the laboratory were
incubated in BACTEC 9240 system. Positive blood culture
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Objectives: To determine the minimum inhibitory concentrations (MICs) of ceftriaxone, azithromycin, pefloxacin,
cefipime and imipenem for Salmonella Typhi (S. Typhi) and Paratyphi. 
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0.5µg/ml. None of the strains were found to be resistant to ceftriaxone but 3 isolates showed higher MIC value
of 2µg/ml. 
Conclusion: Azithromycin appears a suitable alternate for the treatment of typhoid in the community. Imipenem
and cefipime are good options in complicated cases to be treated in hospital settings. Pefloxacin cannot be used
as MICs are higher. Presence of isolates with higher MIC of ceftriaxone is serious and stresses upon continuous
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bottles were sub cultured on suitable medium according to
gram stain findings. Non-lactose fermenting colonies
growing on MacConkey agar were identified by standard
biochemical and serological tests.14
Antimicrobial susceptibility testing (AST) against
ampicillin (AMP) 10µg (Oxoid), co-trimoxazole (SXT) 25
µg, chloramphenicol (C) 30µg, nalidixic acid (NA) 30µg,
ofloxacin (OFX) 5µg and ceftriaxone (CRO) 30µg were
performed by CLSI (Clinical Laboratory Standard Institute)
recommended Kirby-Bauer disk diffusion method.15
Breakpoints of zone sizes were taken from CLSI. For
interpretation of fluoroquinolones, strains which are sensitive
to nalidixic acid were considered sensitive to
fluoroquinolones and for strains which were resistant to
nalidixic acid; MIC of ofloxacin was determined by agar
dilution method as recommended by CLSI guideline.15
Isolates having MIC > 4µg/ml and > 2 µg/ml were considered
resistant and intermediate respectively and those having MIC
< 0.125µg/ml were taken as sensitive. Isolates were
considered to have reduced susceptibility to fluoroquinolones
if MIC was in the range of 0.25µg/ml to1µg/ml.16
MICs of ceftriaxone, azithromycin, pefloxacin
cefipime, and imipenem were performed by agar dilution
method. To perform MIC's antibiotic powders (Sigma
Aldrich) were reconstituted with CLSI recommended
diluents to yield stock solutions.15 Stock solution once made
was kept frozen. Antibiotic dilutions were prepared according
to break points used and at least four fold dilutions below the
sensitive point and four fold above the resistant point were
made. MIC was determined by inoculating the organisms on
Mueller Hinton agar with antibiotics in two fold serial
dilutions and the lowest concentration of drug which
completely inhibited the bacterial growth was recorded as
MIC for that isolate. The drug dilutions at which 50% and
90% of tested isolates got inhibited were recorded as MIC50
& MIC90 respectively as per standard methods.17
Escherichia coli ATCC 25922 and Staphylococcus aureus
ATCC 29213 were included in each experiment to ensure
quality control. MIC breakpoints for ceftriaxone, cefipime
and imipenem were taken from CLSI.
Human subjects were not involved directly in this
study, or no intervention was done therefore formal ethical
review was not required.
The data was entered into SPSS (Statistical Package
for Social Sciences) version 16 software for statistical
analysis. For descriptive analysis mean and standard
deviation of continuous variable such as age were reported.
For categorical variable like gender and antibiotic resistance,
frequencies and percentage were calculated.
Results
Total 154 isolates were included in this study.
Analysis of demographic data showed that 90 (58%) isolates
were obtained from male and 64 (42%) from female patients
with mean age of 15±12 years. Out of the total isolate tested,
82 (53.2%) were S. Typhi, 70(45.5%) S. Paratyphi A, 1
(0.6%) S. Paratyphi B and1 (0.6%) S. Paratyphi C.
By disk diffusion method, 47 (30.5%) isolates were
resistant to all three first line agent (MDR). One hundred and
eleven (72%) of the total strains were resistant to nalidixic
acid. Figure1. Among 111 nalidixic acid resistant strains, 18
were resistant, 28 were intermediate, and 65 had reduced
susceptibility to ofloxacin. Figure-2 explains the MIC values
of flouroquinolones for nalidixic acid resistant strains.
Table summarizes the MIC ranges obtained, MIC50,
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Table: MICs of typhoidal Salmonellae by agar dilution method (n=154).
MIC value(µg/ml) / No. of isolates (n=154)
resistance Ceftriaxone Azithromycin Pefloxacin Cefipime Imipenem
16 - 3 - - -
8 - 67 57 - -
4 - 61 25 - -
2 3 19 45 - -
1 1 1 - - -
0.5 3 - 17 - 29
0.25 66 1 1 1 66
0.125 10 - 7 5 36
0.06 45 1 2 81 12
0.03 20 1 - 66 11
0.015 6 - - 1 -
MIC90 0.25 8 8 0.06 0.5
MIC50 0.12 4 4 0.06 0.25
MIC Range 0.015-2 0.03-16 0.06-8 0.015-8 0.03-0.5
Resistance (%) 0 * * 0 0
CLSI break points of MICs for ceftriaxone in µg/ml: S=<8, I=16-32, R=>64. (3 isolates had higher MIC of 2µg/ml),
cefipime in µg/ml: S=<8, I=16, R=>32, imipenem in µg/ml: S=<2, I=8, R=>32
*Resistance % not given as break point not defined.
MIC90 of ceftriaxone, azithromycin, pefloxacin, cefipime,
and imipenem. None of the strains were found to be resistant
to ceftriaxone but 3 isolates showed higher MIC value of
2µg/ml.
Discussion
In this study we evaluated role of newer antimicrobial
agents, already identified to treat resistant cases of typhoid
fever but never been explored in this part of the world.
Azithromycin has been proposed as a promising agent for the
treatment of enteric fever as it is highly effective against
intracellular Salmonellae, defervescence is rapid,
gastrointestinal carriage is eradicated, available in oral form
and can be safely used in paediatric population in the
community.18 MIC90 of azithromycin in our study is 8µg/ml.
Most of the studies have reported MICs of azithromycin in
the range of 4-16 µg/ml8,9 and MIC90 of 8µg/ml which is in
concordance with our finding. Studies have also shown that
azithromycin even at MIC of 8µg/ml is effective as it
achieves high intracellular concentration and causes no
relapses or major side effects.9 So far there is no
recommendation for the break points of azithromycin in
CLSI for typhoidal Salmonellae which is highly desirable and
should be evaluated on the basis of large clinical trials to
include such useful drug in treatment plans for enteric fever. 
Pefloxacin is an analog of norfloxacin. It has extended
gram negative coverage and has been reported to have higher
cure rate in shorter duration in enteric fever treatment.12
Breakpoints are not yet defined by CLSI. Unal et al in 1996
reported MIC90 of pefloxacin as low as 0.05µg/ml with a
range of (0.06-1µg/ml),12 MIC90 of pefloxacin in our study
is 8µg/ml which indicates rising MIC's and possibly
development of resistance in Salmonellae against this drug
along with other quinolones. The fact which led this drug no
longer a treatment option for typhoid fever.
Imipenem and cefipime showed promising results
with low MIC90. However, their role in enteric fever
treatment needs to be evaluated by clinical trials. Major
limitations of both drugs are high cost and non-availability in
oral forms. Furthermore these drugs are very broad spectrum
and are potent extended spectrum beta lactamase inducers,
use of these drugs in community will select out resistant
microorganism. However their susceptibility against S. Typhi
is important to know as both agents can be used in
complicated typhoid cases and in mixed intraabdominal
infection with Salmonella spp and other gram negative rods
like in cases of intestinal perforation.
None of the strains were found resistant to ceftriaxone
in this study; however three strains with comparatively higher
MICs (2µg/ml) of ceftriaxone were detected. Previously
resistant cases have been reported from Bangladesh and
India. Capoor et al had compared MIC90of third generation
cephalosporin for isolates of 2001 and 2006.6 They reported
MIC90of of 178 strains isolated in 2001 equal to 0.06µg/ml
which risen up to 0.25 µg/ml in 2005 which is in consistent
with MIC90 of our study. Saha et al also reported a case with
very high MIC of ceftriaxone 256 µg/ml.5 These reports from
neighboring countries posing a serious threat. Therefore,
there is a dire need to establish national and regional
surveillance centers to monitor the trend and to develop
strategies to control the emergence of drug resistance and
their further spread. These findings make ceftriaxone's
resistance monitoring and search of alternative drugs an
essential element to control typhoid fever.
Due to irrational use of antibiotics, emergence of drug
resistance is an issue in most of the developing countries
including Pakistan. Resistance in S. Typhi and S. Paratyphi A
to first line drugs and to fluoroquinolones was first reported
from this part of the world and is still prevailing in this
region. According to previous published report from our
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Figure-1: Antibiogram of typhoidal Salmonellae by disk diffusion method showing
resistance against conventional drugs (n=154).
Figure-2: MIC values of ofloxacin for nalidixic acid resistant strains (n=154).
institute,19 none of the S. Typhi isolate had ofloxacin MIC >
4µg/ml in 2001, while in the current study this has risen upto
12%. The reason for this escalation in MIC could be
multifactorial including its overuse in community, over the
counter sale of antibiotics, their easy availability in oral form
and comparatively low cost.
Another interesting and encouraging finding of this
study was decreasing trend of MDR strains. Incidence of
MDR strains was reported up to 70% from Pakistan in
1990s.20 In the current study MDR strains were 47(30.5%) of
the total isolates, this declining trend is noted in other studies
in Pakistan21,22 as well as in other parts of world.23,24 This re
emergence may be because of new susceptible strains or
because of loss of resistant plasmid. This finding invites
future studies to determine molecular basis behind this
phenomenon. 
In conclusion, high prevalence of enteric fever in
Pakistan and consistent emergence of drug resistance,
stresses upon the implementation of preventive measures,
improvement in hygienic conditions, ongoing surveillance
and legislations for judicious use of antibiotics. This study
calls for additional researches to determine dosage, clinical
efficacy of the tested antibiotics. 
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